Accumulating evidence indicates that the therapeutic efficacy of many anti‐tumor approaches, including immunotherapy, is largely dependent on type I interferon signaling.[41] As a key transducer in innate immunity, STING detects cytoplasmic DNA abnormalities, which phosphorylates TBK1 and IRF3, which subsequently triggers the production of type I interferon and pro‐inflammatory cytokines. The gene discussed is STING1; the disease is neoplasm.